Report cover image

Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

Publisher Fortune Business Insights Pvt. Ltd.
Published Mar 01, 2026
Length 278 Pages
SKU # FOB21037240

Description

Growth Factors of metastatic castration-resistant prostate cancer (mCRPC) therapeutics Market

The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market is on a rapid growth trajectory, driven by the rising prevalence of advanced prostate cancer and the increasing demand for effective treatment options. The market was valued at USD 21.04 billion in 2025, projected to grow to USD 29.08 billion in 2026, and is expected to reach USD 91.85 billion by 2034, reflecting a CAGR of 15.46% during the forecast period. North America dominated the market in 2025, holding a 87.63% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and extensive research and development activities.

mCRPC is an advanced form of prostate cancer where tumors no longer fully respond to androgen deprivation therapy (ADT) and may spread to bones, lymph nodes, liver, lungs, and the brain. The aggressive nature of this cancer, combined with high morbidity and mortality, creates an urgent need for novel therapeutics. According to the World Cancer Research Fund, approximately 1.46 million new cancer cases were registered worldwide in 2022, emphasizing the growing demand for effective treatments.

Market Drivers

The market growth is propelled by several key factors:

Robust drug pipelines: Pharmaceutical companies are actively developing next-generation androgen receptor inhibitors, PARP inhibitors, and CYP17 inhibitors to address the challenges of treatment-resistant prostate cancer.

Collaborations and partnerships: For instance, in July 2022, Merck & Co., Inc. and Orion Corporation co-developed opevesostat (MK-5684/ODM-208), a CYP11A1 inhibitor for mCRPC.

Therapeutic advancements: The launch of innovative combination therapies, such as pairing PARP inhibitors with AR inhibitors, significantly enhances treatment outcomes and combats resistance to ADT.

Market Restraints and Challenges

Despite the positive growth trajectory, several factors limit market expansion:

Resistance to hormonal therapy: Over time, prostate cancer cells may adapt to androgen deprivation, reducing the effectiveness of conventional treatments. Mutations in androgen receptor pathways further contribute to resistance.

Adverse side effects: Drugs like ZYTIGA (abiraterone) and enzalutamide are associated with joint swelling, hypokalemia, edema, diarrhea, and cardiovascular risks, which may lead to discontinuation and impact patient compliance.

Market Opportunities

Emergence of radiotheranostics: Combining diagnostic imaging with targeted therapy allows personalized treatment, improving efficacy while minimizing side effects. For example, in November 2023, Clarity Pharmaceuticals initiated a Phase I/IIa trial for 64Cu/67Cu-SAR-bisPSMA in mCRPC patients.

Growing adoption of combination therapies: Initiatives like Pfizer’s TALAPRO-2 study in October 2024 show improved survival outcomes using PARP inhibitors with androgen receptor inhibitors.

Segmentation Analysis

By Drug Class

Androgen receptor inhibitors dominate the market due to their role in blocking testosterone-driven cancer growth.

GnRH agonists, GnRH receptor antagonists, microtubule inhibitors, and PARP inhibitors are projected to grow steadily due to new approvals and collaborations.

By Route of Administration

Oral therapies dominate due to convenience, patient adherence, and better compliance.

Parenteral therapies are growing through innovative clinical trials, such as Actinium-225 by POINT Biopharma (April 2024).

By Therapy

Hormonal therapy leads, supported by widespread adoption of androgen deprivation therapy and availability of generics like Abiraterone Acetate.

Targeted therapy and immunotherapy segments are expanding, while chemotherapy holds a smaller share due to side effects.

By Distribution Channel

Hospital pharmacies dominate, owing to advanced healthcare infrastructure.

Retail and online pharmacies are growing due to convenience and accessibility.

Regional Insights

North America: Market size USD 11.31 billion in 2025, supported by the U.S. and Canada’s robust healthcare systems, reimbursement policies, and R&D.

Europe: Rising awareness campaigns and new diagnostic tools propel growth. For example, a new 'super test' developed in Cambridge (February 2025) enables early detection.

Asia Pacific: Fastest-growing region with a CAGR of 13.6%, fueled by increasing prostate cancer prevalence and research funding initiatives.

Latin America & Middle East & Africa: Moderate growth is anticipated, with increased government initiatives and expansion of cancer care centers.

Key Industry Players

Leading companies such as Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AbbVie Inc., and AstraZeneca dominate the market through extensive product portfolios, regulatory approvals, collaborations, and new launches. Notable developments include:

August 2023: FDA approval of AKEEGA (niraparib + abiraterone) for mCRPC by Johnson & Johnson.

June 2023: AstraZeneca’s Lynparza (olaparib) approved for patients with BRCA mutations.

December 2022: Novartis’ Pluvicto approved by European Commission as targeted radioligand therapy.

Conclusion

The global metastatic castration-resistant prostate cancer therapeutics market is projected to grow from USD 21.04 billion in 2025 to USD 91.85 billion by 2034, at a CAGR of 15.46%. Market expansion is driven by the rising prevalence of advanced prostate cancer, robust R&D pipelines, innovative combination therapies, and emerging radiotheranostics. North America dominates, while Asia Pacific represents the fastest-growing region. Leading companies’ strategic initiatives, product launches, and research collaborations are expected to sustain market growth and enhance treatment outcomes for mCRPC patients globally.

ATTRIBUTE DETAILS

Study Period 2021-2034

Base Year 2025

Estimated Year 2026

Forecast Period 2026-2034

Historical Period 2021-2024

Growth Rate CAGR of 15.46% from 2026-2034

Unit Value (USD Billion)

Segmentation By Drug Class

Androgen Receptor Inhibitors

Microtubule Inhibitors

Gonadotropin Releasing Hormone (GnRH) Agonist

Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist

Others

By Route of Administration

Oral

Parenteral

By Therapy

Chemotherapy

Hormonal Therapy

Targeted therapy

Immunotherapy

By Distribution Channel

Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

By Geography

North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
  • U.S.
  • Canada
Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
Middle East & Africa ( By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa


Please Note: It will take 2-3 business days to complete the report upon order confirmation.

Table of Contents

278 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of key Indications, 2025(Key Countries)
4.2. Economic cost Burden, Chronic Wounds (Key Countries)
4.3. Reimbursement Scenario, Key Countries
4.4. Pricing Analysis, 2021
4.5. Impact of Covid-19 on the Wound Care Devices Market
5. Global Wound Care Devices Market Analysis, Insights and Forecast, 2021-2034
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Product
5.2.1. Negative Pressure Wound Therapy
5.2.2. Hyperbaric Oxygen Therapy
5.2.3. Extracorporeal Shock Wave Therapy
5.2.4. Others (Compression Therapy, etc.)
5.3. Market Analysis, Insights and Forecast – By Indication
5.3.1. Diabetic Foot Ulcers
5.3.2. Pressure Ulcers
5.3.3. Surgical Wounds
5.3.4. Others
5.4. Market Analysis, Insights and Forecast – By End User
5.4.1. Hospitals
5.4.2. Clinics
5.4.3. Home Care Settings
5.4.4. Others
5.5. Market Analysis, Insights and Forecast – By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
6. North America Wound Care Devices Market Analysis, Insights and Forecast, 2021-2034
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Product
6.2.1. Negative Pressure Wound Therapy
6.2.2. Hyperbaric Oxygen Therapy
6.2.3. Extracorporeal Shock Wave Therapy
6.2.4. Others (Compression Therapy, etc.)
6.3. Market Analysis, Insights and Forecast – By Indication
6.3.1. Diabetic Foot Ulcers
6.3.2. Pressure Ulcers
6.3.3. Surgical Wounds
6.3.4. Others
6.4. Market Analysis, Insights and Forecast – By End User
6.4.1. Hospitals
6.4.2. Clinics
6.4.3. Home Care Settings
6.4.4. Others
6.5. Market Analysis, Insights and Forecast – By Country
6.5.1. U.S.
6.5.2. Canada
7. Europe Wound Care Devices Market Analysis, Insights and Forecast, 2021-2034
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Product
7.2.1. Negative Pressure Wound Therapy
7.2.2. Hyperbaric Oxygen Therapy
7.2.3. Extracorporeal Shock Wave Therapy
7.2.4. Others (Compression Therapy, etc.)
7.3. Market Analysis, Insights and Forecast – By Indication
7.3.1. Diabetic Foot Ulcers
7.3.2. Pressure Ulcers
7.3.3. Surgical Wounds
7.3.4. Others
7.4. Market Analysis, Insights and Forecast – By End User
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Home Care Settings
7.4.4. Others
7.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
7.5.1. Germany
7.5.2. U.K.
7.5.3. France
7.5.4. Italy
7.5.5. Spain
7.5.6. Scandinavia
7.5.7. Rest of Europe
8. Asia Pacific Wound Care Devices Market Analysis, Insights and Forecast, 2021-2034
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Product
8.2.1. Negative Pressure Wound Therapy
8.2.2. Hyperbaric Oxygen Therapy
8.2.3. Extracorporeal Shock Wave Therapy
8.2.4. Others (Compression Therapy, etc.)
8.3. Market Analysis, Insights and Forecast – By Indication
8.3.1. Diabetic Foot Ulcers
8.3.2. Pressure Ulcers
8.3.3. Surgical Wounds
8.3.4. Others
8.4. Market Analysis, Insights and Forecast – By End User
8.4.1. Hospitals
8.4.2. Clinics
8.4.3. Home Care Settings
8.4.4. Others
8.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. Australia
8.5.5. Southeast Asia
8.5.6. Rest of Asia Pacific
9. Latin America Wound Care Devices Market Analysis, Insights and Forecast, 2021-2034
9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast – By Product
9.2.1. Negative Pressure Wound Therapy
9.2.2. Hyperbaric Oxygen Therapy
9.2.3. Extracorporeal Shock Wave Therapy
9.2.4. Others (Compression Therapy, etc.)
9.3. Market Analysis, Insights and Forecast – By Indication
9.3.1. Diabetic Foot Ulcers
9.3.2. Pressure Ulcers
9.3.3. Surgical Wounds
9.3.4. Others
9.4. Market Analysis, Insights and Forecast – By End User
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Home Care Settings
9.4.4. Others
9.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East & Africa Wound Care Devices Market Analysis, Insights and Forecast, 2021-2034
10.1. Key Findings / Summary
10.2. Market Analysis, Insights and Forecast – By Product
10.2.1. Negative Pressure Wound Therapy
10.2.2. Hyperbaric Oxygen Therapy
10.2.3. Extracorporeal Shock Wave Therapy
10.2.4. Others (Compression Therapy, etc.)
10.3. Market Analysis, Insights and Forecast – By Indication
10.3.1. Diabetic Foot Ulcers
10.3.2. Pressure Ulcers
10.3.3. Surgical Wounds
10.3.4. Others
10.4. Market Analysis, Insights and Forecast – By End User
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Home Care Settings
10.4.4. Others
10.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
10.5.1. South Africa
10.5.2. GCC
10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2021)
11.3. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
11.3.1. Smith & Nephew
11.3.1.1. Overview,
11.3.1.2. Products,
11.3.1.3. SWOT Analysis,
11.3.1.4. Recent Developments,
11.3.1.5. Strategies,
11.3.1.6. Financials (Based on Availability)
11.3.2. Talley Group Ltd
11.3.2.1. Overview,
11.3.2.2. Products,
11.3.2.3. SWOT Analysis,
11.3.2.4. Recent Developments,
11.3.2.5. Strategies,
11.3.2.6. Financials (Based on Availability)
11.3.3. Cardinal Health
11.3.3.1. Overview,
11.3.3.2. Products,
11.3.3.3. SWOT Analysis,
11.3.3.4. Recent Developments,
11.3.3.5. Strategies,
11.3.3.6. Financials (Based on Availability)
11.3.4. ConvaTec Inc.
11.3.4.1. Overview,
11.3.4.2. Products,
11.3.4.3. SWOT Analysis,
11.3.4.4. Recent Developments,
11.3.4.5. Strategies,
11.3.4.6. Financials (Based on Availability)
11.3.5. DeRoyal Industries, Inc.
11.3.5.1. Overview,
11.3.5.2. Products,
11.3.5.3. SWOT Analysis,
11.3.5.4. Recent Developments,
11.3.5.5. Strategies,
11.3.5.6. Financials (Based on Availability)
11.3.6. Devon Medical Products
11.3.6.1. Overview,
11.3.6.2. Products,
11.3.6.3. SWOT Analysis,
11.3.6.4. Recent Developments,
11.3.6.5. Strategies,
11.3.6.6. Financials (Based on Availability)
11.3.7. BSN Medical
11.3.7.1. Overview,
11.3.7.2. Products,
11.3.7.3. SWOT Analysis,
11.3.7.4. Recent Developments,
11.3.7.5. Strategies,
11.3.7.6. Financials (Based on Availability)
11.3.8. Medela AG
11.3.8.1. Overview,
11.3.8.2. Products,
11.3.8.3. SWOT Analysis,
11.3.8.4. Recent Developments,
11.3.8.5. Strategies,
11.3.8.6. Financials (Based on Availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us